Multimodality imaging characteristics of dementia with Lewy bodies

Neurobiology of Aging

Volumn 33, Issue 9, 2012, Pages 2091-2105

  Kantarci, Kejal ^a   Lowe, Val J ^a   Boeve, Bradley F ^a   Weigand, Stephen D ^a   Senjem, Matthew L ^a   Przybelski, Scott A ^a   Dickson, Dennis W ^b   Parisi, Joseph E ^a   Knopman, David S ^a   Smith, Glenn E ^a   Ferman, Tanis J ^b   Petersen, Ronald C ^a   Jack, Clifford R ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Alzheimer's disease; Dementia with Lewy bodies; FDG; MRI; PET; PiB

Indexed keywords

PITTSBURGH COMPOUND B;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX ATROPHY; BRAIN METABOLISM; CLINICAL ARTICLE; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; FEMALE; GLUCOSE METABOLISM; HUMAN; MALE; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANILINE COMPOUNDS; BRAIN MAPPING; CASE-CONTROL STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGING, THREE-DIMENSIONAL; LEWY BODY DISEASE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OCCIPITAL LOBE; POSITRON-EMISSION TOMOGRAPHY; ROC CURVE; STATISTICS, NONPARAMETRIC; THIAZOLES;

EID: 84863448289     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.09.024     Document Type: Article

References (101)

1. International Classification of Sleep Disorders-2: Diagnostic and Coding Manual 2005, AASM, American Academy of Sleep Medicine, Chicago.
2. Aharon-Peretz J., Israel O., Goldsher D., Peretz A. Posterior cortical atrophy variants of Alzheimer's disease. Dement. Geriatr. Cogn. Disord 1999, 10:483-487.
3. Albin R.L., Minoshima S., D'Amato C.J., Frey K.A., Kuhl D.A., Sima A.A. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996, 47:462-466.
4. Ashburner J., Friston K.J. Unified segmentation. Neuroimage 2005, 26:839-851.
5. Barber R., Gholkar A., Scheltens P., Ballard C., McKeith I.G., O'Brien J.T. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 1999, 52:1153-1158.
6. Barker W.W., Luis C.A., Kashuba A., Luis M., Harwood D.G., Loewenstein D., Waters C., Jimison P., Shepherd E., Sevush S., Graff-Radford N., Newland D., Todd M., Miller B., Gold M., Heilman K., Doty L., Goodman I., Robinson B., Pearl G., Dickson D., Duara R. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis. Assoc. Disord 2002, 16:203-212.
7. Barkhof F., Polvikoski T.M., van Straaten E.C., Kalaria R.N., Sulkava R., Aronen H.J., Niinistö L., Rastas S., Oinas M., Scheltens P., Erkinjuntti T. The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology 2007, 69:1521-1527.
8. Bobinski M., Wegiel J., Tarnawski M., Bobinski M., Reisberg B., de Leon M.J., Miller D.C., Wisniewski H.M. Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. J. Neuropathol. Exp. Neurol 1997, 56:414-420.
9. Bohnen N.I., Frey K.A. Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders. Mol. Imaging Biol 2007, 9:243-257.
10. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
11. Burack M.A., Hartlein J., Flores H.P., Taylor-Reinwald L., Perlmutter J.S., Cairns N.J. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010, 74:77-84.
12. Burton E.J., Barber R., Mukaetova-Ladinska E.B., Robson J., Perry R.H., Jaros E., Kalaria R.N., O'Brien J.T. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 2009, 132:195-203.
13. Burton E.J., Karas G., Paling S.M., Barber R., Williams E.D., Ballard C.G., McKeith I.G., Scheltens P., Barkhof F., O'Brien J.T. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 2002, 17:618-630.
14. Burton E.J., Mukaetova-Ladinska E.B., Perry R.H., Jaros E., Barber R., O'Brien J.T. Neuropathological correlates of volumetric MRI in autopsy-confirmed Lewy body dementia. Neurobiol. Aging 2011, 2011 Feb 23. [Epub ahead of print]. 10.1016/j.neurobiolaging.2010.12.015.
15. Ceravolo R., Volterrani D., Gambaccini G., Bernardini S., Rossi C., Logi C., Tognoni G., Manca G., Mariani G., Bonuccelli U., Murri L. Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study. J. Neural Transm 2004, 111:1065-1073.
16. Csernansky J.G., Hamstra J., Wang L., McKeel D., Price J.L., Gado M., Morris J.C. Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects. Alzheimer Dis. Assoc. Disord 2004, 18:190-195.
17. Dickson D.W. Dementia with Lewy bodies: neuropathology. J. Geriatr. Psychiatry Neurol 2002, 15:210-216.
18. Dickson D.W., Crystal H.A., Bevona C., Honer W., Vincent I., Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging 1995, 16:285-298. Discussion, 98-304.
19. Dickson D.W., Ruan D., Crystal H., Mark M.H., Davies P., Kress Y., Yen S.H. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology 1991, 41:1402-1409.
20. Edison P., Rowe C.C., Rinne J.O., Ng S., Ahmed I., Kemppainen N., Villemagne V.L., O'Keefe G., Nagren K., Chaudhury K.R., Masters C.L., Brooks D.J. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J. Neurol. Neurosurg. Psychiatry 2008, 79:1331-1338.
21. Ferman T.J., Smith G.E., Boeve B.F., Ivnik R.J., Petersen R.C., Knopman D., Graff-Radford N., Parisi J., Dickson D.W. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004, 62:181-187.
22. Firbank M.J., Blamire A.M., Teodorczuk A., Teper E., Burton E.J., Mitra D., O'Brien J.T. High resolution imaging of the medial temporal lobe in Alzheimer's disease and dementia with Lewy bodies. J. Alzheimers Dis 2010, 21:1129-1140.
23. Fodero-Tavoletti M.T., Smith D.P., McLean C.A., Adlard P.A., Barnham K.J., Foster L.E., Leone L., Perez K., Cortés M., Culvenor J.G., Li Q.X., Laughton K.M., Rowe C.C., Masters C.L., Cappai R., Villemagne V.L. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J. Neurosci 2007, 27:10365-10371.
24. Foster E.R., Campbell M.C., Burack M.A., Hartlein J., Flores H.P., Cairns N.J., Hershey T., Perlmutter J.S. Amyloid imaging of Lewy body-associated disorders. Mov. Disord 2010, 25:2516-2523.
25. Fujishiro H., Ferman T.J., Boeve B.F., Smith G.E., Graff-Radford N.R., Uitti R.J., Wszolek Z.K., Knopman D.S., Petersen R.C., Parisi J.E., Dickson D.W. Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J. Neuropathol. Exp. Neurol 2008, 67:649-656.
26. Fujishiro H., Iseki E., Higashi S., Kasanuki K., Murayama N., Togo T., Katsuse O., Uchikado H., Aoki N., Kosaka K., Arai H., Sato K. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Neurosci. Lett 2010, 486:19-23.
27. Galasko D., Hansen L.A., Katzman R., Wiederholt W., Masliah E., Terry R., Hill L.R., Lessin P., Thal L.J. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch. Neurol 1994, 51:888-895.
28. Giannakopoulos P., Hof P.R., Mottier S., Michel J.P., Bouras C. Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: retrospective clinicopathological evaluation of a 10-year autopsy population. Acta Neuropathol 1994, 87:456-468.
29. Gilman S., Koeppe R.A., Little R., An H., Junck L., Giordani B., Persad C., Heumann M., Wernette K. Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. Ann. Neurol 2004, 55:774-780.
30. Gómez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E., Hyman B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol 1997, 41:17-24.
31. Gómez-Tortosa E., Newell K., Irizarry M.C., Albert M., Growdon J.H., Hyman B.T. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 1999, 53:1284-1291.
32. Gomperts S.N., Rentz D.M., Moran E., Becker J.A., Locascio J.J., Klunk W.E., Mathis C.A., Elmaleh D.R., Shoup T., Fischman A.J., Hyman B.T., Growdon J.H., Johnson K.A. Imaging amyloid deposition in Lewy body diseases. Neurology 2008, 71:903-910.
33. Gosche K.M., Mortimer J.A., Smith C.D., Markesbery W.R., Snowdon D.A. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 2002, 58:1476-1482.
34. Grober E., Dickson D., Sliwinski M.J., Buschke H., Katz M., Crystal H., Lipton R.B. Memory and mental status correlates of modified Braak staging. Neurobiol. Aging 1999, 20:573-579.
35. Guillozet A.L., Weintraub S., Mash D.C., Mesulam M.M. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch. Neurol 2003, 60:729-736.
36. Hansen L., Salmon D., Galasko D., Masliah E., Katzman R., DeTeresa R., Thal L., Pay M.M., Hofstetter R., Klauber M., et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990, 40:1-8.
37. Regression Modeling Strategies 2001, Springer, New York. F.E.J. Harrell (Ed.).
38. Higuchi M., Tashiro M., Arai H., Okamura N., Hara S., Higuchi S., Itoh M., Shin R.W., Trojanowski J.Q., Sasaki H. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp. Neurol 2000, 162:247-256.
39. Hof P.R., Vogt B.A., Bouras C., Morrison J.H. Atypical form of Alzheimer's disease with prominent posterior cortical atrophy: a review of lesion distribution and circuit disconnection in cortical visual pathways. Vision Res 1997, 37:3609-3625.
40. Hyman B.T., Trojanowski J.Q. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J. Neuropathol. Exp. Neurol 1997, 56:1095-1097.
41. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Mathis C.A., Price J.C., Tsopelas N.D., Lopresti B.J., Ziolko S., Bi W., Paljug W.R., Debnath M.L., Hope C.E., Isanski B.A., Hamilton R.L., Dekosky S.T. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645.
42. Imamura T., Ishii K., Hirono N., Hashimoto M., Tanimukai S., Kazuai H., Hanihara T., Sasaki M., Mori E. Visual hallucinations and regional cerebral metabolism in dementia with Lewy bodies (DLB). Neuroreport 1999, 10:1903-1907.
43. Imamura T., Ishii K., Sasaki M., Kitagaki H., Yamaji S., Hirono N., Shimomura T., Hashimoto M., Tanimukai S., Kazui H., Mori E. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography. Neurosci. Lett 1997, 235:49-52.
44. Ishii K., Imamura T., Sasaki M., Yamaji S., Sakamoto S., Kitagaki H., Hashimoto M., Hirono N., Shimomura T., Mori E. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 1998, 51:125-130.
45. Ishii K., Sasaki M., Kitagaki H., Yamaji S., Sakamoto S., Matsuda K., Mori E. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. J. Nucl. Med 1997, 38:925-928.
46. Jack C.R., Dickson D.W., Parisi J.E., Xu Y.C., Cha R.H., O'Brien P.C., Edland S.D., Smith G.E., Boeve B.F., Tangalos E.G., Kokmen E., Petersen R.C. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002, 58:750-757.
47. Jack C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., Knopman D.S., Boeve B.F., Klunk W.E., Mathis C.A., Petersen R.C. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131:665-680.
48. Jagust W.J., Zheng L., Harvey D.J., Mack W.J., Vinters H.V., Weiner M.W., Ellis W.G., Zarow C., Mungas D., Reed B.R., Kramer J.H., Schuff N., DeCarli C., Chui H.C. Neuropathological basis of magnetic resonance images in aging and dementia. Ann. Neurol 2008, 63:72-80.
49. Joachim C.L., Morris J.H., Selkoe D.J. Clinically diagnosed Alzheimer's disease: autopsy results in 150 cases. Ann. Neurol 1988, 24:50-56.
50. Kalaitzakis M.E., Walls A.J., Pearce R.K., Gentleman S.M. Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and PDD from other Parkinsonian syndromes. Neurobiol. Dis 2011, 41:377-384.
51. Kantarci K., Dickson D.W., Vemuri P., Ferman T.J., Boeve B.F., Smith G.E., Senjem M.L., Parisi J.E., Weigand S.D., Murray M.M., Knopman D.S., Petersen R.C., Jack C.R. Ante mortem Hippocampal Atrophy Predicts Presence of Alzheimer's Disease Pathology in Pathologically Proven Lewy Body Disease. Neurology 2011, 76(suppl 4):A176.
52. Kantarci K., Senjem M.L., Lowe V.J., Wiste H.J., Weigand S.D., Kemp B.J., Frank A.R., Shiung M.M., Boeve B.F., Knopman D.S., Petersen R.C., Jack C.R. Effects of age on the glucose metabolic changes in mild cognitive impairment. AJNR Am. J. Neuroradiol 2010, 31:1247-1253.
53. Kantarci K., Yang C., Schneider J.A., Senjem M.L., Reyes D.A., Lowe V.J., Barnes L.L., Aggarwal N.T., Bennett D.A., Smith G.E., Petersen R.C., Jack C.R., Boeve B.F. Ante mortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol. Aging 2010, 2010 Oct 18 [Epub ahead of print]. 10.1016/j.neurobiolaging.2010.08.007.
54. Koeppe R.A., Gilman S., Joshi A., Liu S., Little R., Junck L., Heumann M., Frey K.A., Albin R.L. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J. Nucl. Med 2005, 46:936-944.
55. Kramer M.L., Schulz-Schaeffer W.J. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci 2007, 27:1405-1410.
56. Lim S.M., Katsifis A., Villemagne V.L., Best R., Jones G., Saling M., Bradshaw J., Merory J., Woodward M., Hopwood M., Rowe C.C. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J. Nucl. Med 2009, 50:1638-1645.
57. Lippa C.F., Johnson R., Smith T.W. The medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer's disease. Ann. Neurol 1998, 43:102-106.
58. Lockhart A., Lamb J.R., Osredkar T., Sue L.I., Joyce J.N., Ye L., Libri V., Leppert D., Beach T.G. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 2007, 130:2607-2615.
59. Lowe V.J., Kemp B.J., Jack C.R., Senjem M., Weigand S., Shiung M., Smith G., Knopman D., Boeve B., Mullan B., Petersen R.C. Comparison of 18F-FDG and PiB PET in cognitive impairment. J. Nucl. Med 2009, 50:878-886.
60. Luis C.A., Barker W.W., Gajaraj K., Harwood D., Petersen R., Kashuba A., Waters C., Jimison P., Pearl G., Petito C., Dickson D., Duara R. Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample. Int. J. Geriatr. Psychiatry 1999, 14:526-533.
61. Maetzler W., Liepelt I., Reimold M., Reischl G., Solbach C., Becker C., Schulte C., Leyhe T., Keller S., Melms A., Gasser T., Berg D. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol. Dis 2009, 34:107-112.
62. McKeith I., O'Brien J., Walker Z., Tatsch K., Booij J., Darcourt J., Padovani A., Giubbini R., Bonuccelli U., Volterrani D., Holmes C., Kemp P., Tabet N., Meyer I., Reininger C. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007, 6:305-313. DLB Study Group.
63. McKeith I.G., Ballard C.G., Perry R.H., Ince P.G., O'Brien J.T., Neill D., Lowery K., Jaros E., Barber R., Thompson P., Swann A., Fairbairn A.F., Perry E.K. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000, 54:1050-1058.
64. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., Aarsland D., Arai H., Ballard C.G., Boeve B., Burn D.J., Costa D., Del Ser T., Dubois B., Galasko D., Gauthier S., Goetz C.G., Gomez-Tortosa E., Halliday G., Hansen L.A., Hardy J., Iwatsubo T., Kalaria R.N., Kaufer D., Kenny R.A., Korczyn A., Kosaka K., Lee V.M., Lees A., Litvan I., Londos E., Lopez O.L., Minoshima S., Mizuno Y., Molina J.A., Mukaetova-Ladinska E.B., Pasquier F., Perry R.H., Schulz J.B., Trojanowski J.Q., Yamada M. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872. Consortium on DLB.
65. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
66. Meltzer C.C., Kinahan P.E., Greer P.J., Nichols T.E., Comtat C., Cantwell M.N., Lin M.P., Price J.C. Comparative evaluation of MR-based partial-volume correction schemes for PET. J. Nucl. Med 1999, 40:2053-2065.
67. Merdes A.R., Hansen L.A., Jeste D.V., Galasko D., Hofstetter C.R., Ho G.J., Thal L.J., Corey-Bloom J. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003, 60:1586-1590.
68. Minoshima S., Foster N.L., Sima A.A., Frey K.A., Albin R.L., Kuhl D.E. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann. Neurol 2001, 50:358-365.
69. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD).
70. Mori T., Ikeda M., Fukuhara R., Nestor P.J., Tanabe H. Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB. Neurology 2006, 66:935-937.
71. Mosconi L., Tsui W.H., Herholz K., Pupi A., Drzezga A., Lucignani G., Reiman E.M., Holthoff V., Kalbe E., Sorbi S., Diehl-Schmid J., Perneczky R., Clerici F., Caselli R., Beuthien-Baumann B., Kurz A., Minoshima S., de Leon M.J. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J. Nucl. Med 2008, 49:390-398.
72. Nagy Z., Esiri M.M., Jobst K.A., Morris J.H., King E.M., McDonald B., Litchfield S., Smith A., Barnetson L., Smith A.D. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia 1995, 6:21-31.
73. O'Brien J.T., Colloby S., Fenwick J., Williams E.D., Firbank M., Burn D., Aarsland D., McKeith I.G. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch. Neurol 2004, 61:919-925.
74. O'Brien J.T., McKeith I.G., Walker Z., Tatsch K., Booij J., Darcourt J., Marquardt M., Reininger C. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br. J. Psychiatry 2009, 194:34-39. DLB Study Group.
75. Perneczky R., Drzezga A., Boecker H., Förstl H., Kurz A., Häussermann P. Cerebral metabolic dysfunction in patients with dementia with Lewy bodies and visual hallucinations. Dement. Geriatr. Cogn. Disord 2008, 25:531-538.
76. Quigley H., Colloby S.J., O'Brien J.T. PET imaging of brain amyloid in dementia: a review. Int. J. Geriatr. Psychiatry 2011, 26:991-999.
77. Roberts R.O., Geda Y.E., Knopman D.S., Cha R.H., Pankratz V.S., Boeve B.F., Ivnik R.J., Tangalos E.G., Petersen R.C., Rocca W.A. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008, 30:58-69.
78. Rocher A.B., Chapon F., Blaizot X., Baron J.C., Chavoix C. Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage 2003, 20:1894-1898.
79. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W.E., Mathis C.A., Price J.C., Masters C.L., Villemagne V.L. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
80. Sabattoli F., Boccardi M., Galluzzi S., Treves A., Thompson P.M., Frisoni G.B. Hippocampal shape differences in dementia with Lewy bodies. Neuroimage 2008, 41:699-705.
81. Satoh M., Ishikawa H., Meguro K., Kasuya M., Ishii H., Yamaguchi S. Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project. Eur. Neurol 2010, 64:337-344.
82. Schneider J.A., Arvanitakis Z., Bang W., Bennett D.A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007, 69:2197-2204.
83. Seibyl J.P., Laruelle M., van Dyck C.H., Wallace E., Baldwin R.M., Zoghbi S., Zea-Ponce Y., Neumeyer J.L., Charney D.S., Hoffer P.B., Innis R.B. Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters. J. Nucl. Med 1996, 37:222-228.
84. Shimada H., Hirano S., Shinotoh H., Aotsuka A., Sato K., Tanaka N., Ota T., Asahina M., Fukushi K., Kuwabara S., Hattori T., Suhara T., Irie T. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009, 73:273-278.
85. Silbert L.C., Quinn J.F., Moore M.M., Corbridge E., Ball M.J., Murdoch G., Sexton G., Kaye J.A. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003, 61:487-492.
86. Sojkova J., Driscoll I., Iacono D., Zhou Y., Codispoti K.E., Kraut M.A., Ferrucci L., Pletnikova O., Mathis C.A., Klunk W.E., O'Brien R.J., Wong D.F., Troncoso J.C., Resnick S.M. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch. Neurol 2011, 68:232-240.
87. Tam C.W., Burton E.J., McKeith I.G., Burn D.J., O'Brien J.T. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology 2005, 64:861-865.
88. Tang-Wai D.F., Graff-Radford N.R., Boeve B.F., Dickson D.W., Parisi J.E., Crook R., Caselli R.J., Knopman D.S., Petersen R.C. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004, 63:1168-1174.
89. Teune L.K., Bartels A.L., de Jong B.M., Willemsen A.T., Eshuis S.A., de Vries J.J., van Oostrom J.C., Leenders K.L. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov. Disord 2010, 25:2395-2404.
90. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002, 15:273-289.
91. Vemuri P., Gunter J.L., Senjem M.L., Whitwell J.L., Kantarci K., Knopman D.S., Boeve B.F., Petersen R.C., Jack C.R. Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage 2008, 39:1186-1197.
92. Vemuri P., Simon G., Kantarci K., Whitwell J.L., Senjem M.L., Przybelski S.A., Gunter J.L., Josephs K.A., Knopman D.S., Boeve B.F., Ferman T.J., Dickson D.W., Parisi J.E., Petersen R.C., Jack C.R. Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. Neuroimage 2011, 55:522-531.
93. Vemuri P., Whitwell J.L., Kantarci K., Josephs K.A., Parisi J.E., Shiung M.S., Knopman D.S., Boeve B.F., Petersen R.C., Dickson D.W., Jack C.R. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage 2008, 42:559-567.
94. Verghese J., Crystal H.A., Dickson D.W., Lipton R.B. Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 1999, 53:1974-1982.
95. Walker Z., Jaros E., Walker R.W., Lee L., Costa D.C., Livingston G., Ince P.G., Perry R., McKeith I., Katona C.L. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J. Neurol. Neurosurg. Psychiatry 2007, 78:1176-1181.
96. Whitwell J.L., Josephs K.A., Murray M.E., Kantarci K., Przybelski S.A., Weigand S.D., Vemuri P., Senjem M.L., Parisi J.E., Knopman D.S., Boeve B.F., Petersen R.C., Dickson D.W., Jack C.R. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008, 71:743-749.
97. Whitwell J.L., Weigand S.D., Shiung M.M., Boeve B.F., Ferman T.J., Smith G.E., Knopman D.S., Petersen R.C., Benarroch E.E., Josephs K.A., Jack C.R. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain 2007, 130:708-719.
98. Ye L., Velasco A., Fraser G., Beach T.G., Sue L., Osredkar T., Libri V., Spillantini M.G., Goedert M., Lockhart A. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J. Neurochem 2008, 105:1428-1437.
99. Zaccai J., McCracken C., Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005, 34:561-566.
100. Zaja-Milatovic S., Keene C.D., Montine K.S., Leverenz J.B., Tsuang D., Montine T.J. Selective dendritic degeneration of medium spiny neurons in dementia with Lewy bodies. Neurology 2006, 66:1591-1593.
101. Zarow C., Vinters H.V., Ellis W.G., Weiner M.W., Mungas D., White L., Chui H.C. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia. Ann. Neurol 2005, 57:896-903.